Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Rakesh Bhatia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6428-1022; OpenAlex author ID A5039090834, A5124913936. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 5 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 14

  1. Acinar cell plasticity and subtype specification during acinar-to-ductal metaplasia and pancreatic cancer progression. Last author DOI 10.1016/j.bbcan.2026.189549↗
  2. Ribosome biogenesis, altered metabolism and ribotoxic stress response in pancreatic ductal adenocarcinoma tumor microenvironment. Last author DOI 10.1016/j.canlet.2025.217484↗
  3. Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Co-author DOI 10.1038/s41388-022-02587-1↗
  4. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215922↗
  5. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. Co-author DOI 10.1016/j.semcancer.2022.03.021↗
  6. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance. First author DOI 10.1053/j.gastro.2021.09.017↗
  7. Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-021-01800-4↗
  8. SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00135-21↗
  9. Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1591↗
  10. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β. First author DOI 10.3390/cancers13133105↗
  11. Correction: Kaushal et al. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β. Cancers 2021, 13, 3105. First author DOI 10.3390/cancers13225591↗
  12. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1359↗
  13. Emerging trends in the immunotherapy of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.12.012↗
  14. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/14728222.2017.1323880↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 12 shared papers, 2017–2023 · strength 1.50
  2. Sushil Kumar K · 8 shared papers, 2017–2023 · strength 0.99
  3. Sanjib Chaudhary · 2 shared papers, 2025–2026 · strength 0.70
  4. Ramesh Pothuraju · 2 shared papers, 2025–2026 · strength 0.70
  5. Christopher M. Thompson · 5 shared papers, 2020–2023 · strength 0.66
  6. Andrew C. Cannon · 5 shared papers, 2017–2023 · strength 0.60
  7. Pranita Atri · 4 shared papers, 2020–2022 · strength 0.48
  8. Shailendra Kumar Gautam · 3 shared papers, 2017–2026 · strength 0.47
  9. Satyanarayana Rachagani · 3 shared papers, 2021–2023 · strength 0.43
  10. Jesse L. Cox · 3 shared papers, 2022–2023 · strength 0.40
  11. Koelina Ganguly · 3 shared papers, 2021–2023 · strength 0.39
  12. Sanchita Rauth · 3 shared papers, 2021–2022 · strength 0.36
  13. Xiaoqi Li · 2 shared papers, 2022–2023 · strength 0.34
  14. Bharti Gautam · 1 shared paper, 2026 · strength 0.33
  15. Maneesh Jain · 3 shared papers, 2017–2023 · strength 0.29
  16. Jyoti Kaushal · 2 shared papers, 2021 · strength 0.28
  17. Lynette M. Smith · 2 shared papers, 2021–2022 · strength 0.24
  18. Sushil Kumar · 2 shared papers, 2021 · strength 0.24
  19. Parthasarathy Seshacharyulu · 2 shared papers, 2021–2022 · strength 0.23
  20. Ashu Shah · 2 shared papers, 2021–2022 · strength 0.23
  21. Rama Krishna Nimmakayala · 2 shared papers, 2021–2022 · strength 0.23
  22. Moorthy Palanimuthu Ponnusamy · 2 shared papers, 2021–2022 · strength 0.23
  23. Joyce C. Solheim · 2 shared papers, 2018–2021 · strength 0.22
  24. Namita Bhyravbhatla · 1 shared paper, 2022 · strength 0.19
  25. Naveenkumar Perumal · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.